ob/ob

OB 24 hydrochloride is a selective, orally active HO-1 inhibitor (IC50=1.9 μM) exhibiting antitumor and anti-metastatic properties, suitable for studying prostate cancer, melanoma, ovarian cancer, and lung cancer metastasis.

OB-1 is a protein-like protein-3 (STOML3) inhibitor, inhibiting adipogenesis and lipid droplet growth by downregulating the PPARγ pathway. OB-1 inhibits adipogenesis and lipid droplet growth by interfering with the self-association of stomatin.

OB-2 is an inhibitor of stomatin-like protein-3 (STOML3) oligomerization. OB-2 reversibly reduces the sensitivity of mechanically gated currents in sensory neurons and silence mechanoreceptors in vivo.

OB-24 free base is a potent and selective heme oxygenase 1 (HO-1) inhibitor.

1,2-Bis(4-(benzo[d]oxazol-2-yl)phenyl)ethene (Standard) is the standard substance of 1,2-Bis(4-(benzo[d]oxazol-2-yl)phenyl)ethene, and it is applicable for quantitative analysis, quality control, and related research in biochemical experiments. 1,2-Bis(4-(benzo[d]oxazol-2-yl)phenyl)ethene is a biochemical reagent that can be used as a biomaterial for life science related research and as a sulfonylation reagent for organic synthesis and drug discovery.

[D-Leu-4]-OB3 suppresses the expression of genes associated with inflammation, proliferation, and metastasis, as well as the expression of PD-L1. Additionally, it promotes the expression of genes that induce apoptosis [1].

OB3, a leptin derivative, exhibits greater efficacy than leptin in diminishing obesity and diabetes in mouse models. Additionally, OB3 mitigates leptin-associated inflammation and proliferation in hepatocellular carcinoma cells [1].

Fatostatin hydrobromide (Fatostatin A HBr) ia an inhibitor of sterol regulatory element binding protein (SREBP). It impairs the activation of SREBP-1 and SREBP-2.

Fatostatin is a specific inhibitor of SREBP activation, it impairs the activation of SREBP-1 and SREBP-2. Fatostatin binds to SCAP (SREBP cleavage-activating protein), and inhibits the ER-Golgi translocation of SREBPs.

Talibegron hydrochloride (ZD2079 hydrochloride) is a β3 adrenergic receptor agonist with a pD2 of 3.72 on phenylephrine-preconstricted rat mesenteric artery. It relaxes rat mesenteric artery and isolated aorta in vitro, and inhibits ob gene expression and circulating leptin levels in lean mice in vivo.

Phanginin A, a natural product discovered in Caesalpinia sappan Linn, activates SIK1 and inhibits gluconeogenesis in mouse primary hepatocytes. Phanginin A increases PDE4 activity and suppresses the hepatic cAMP/PKA/CREB pathway, improving metabolic disorders in ob/ob mice. It may be used in studies of type 2 diabetes.

PF-5006739 is a potent and selective CK1δ/ε inhibitor with IC50 values of 3.9 nM and 17.0 nM, respectively.It can be used in the study of psychiatric disorders and exhibits low nanomolar in vitro potency against CK1δ/ε and high kinome selectivity.PF-5006739 dose-dependently reduces opioid-seeking behavior in rodent relapse models and improves glucose tolerance in mouse models of diet-induced obesity (DIO) and genetic obesity (ob/ob).

DDN is a selective Insulin Receptor activator and insulin sensitizer that mimics insulin activity with oral efficacy. It can directly bind to the receptor kinase domain, inducing Akt and ERK phosphorylation, and enhances insulin-stimulated glucose uptake. DDN significantly reduces blood glucose levels in wild-type and diabetic ob/ob and db/db mice.

BVT.13 is an orally active and selective PPARγ agonist with maximal efficacy comparable to rosiglitazone, BVT.13 demonstrates antidiabetic activity in ob/ob mice, showing potential in metabolism research.

AM-2394 is an effective and specific Glucokinase agonist (GKA, EC50: 60 nM), which catalyzes the phosphorylation of glucose to glucose-6-phosphate. AM-2394(AM2394) increases the affinity of GK for glucose by approximately 10-fold, exhibits moderate clearance and good oral bioavailability in multiple animal models, and lowers glucose excursion following an oral glucose tolerance test in an ob/ob mouse model of diabetes.

BR103354 is a novel fibroblast activation protein (FAP) inhibitor with anti-diabetic and anti-steatotic effects. BR103354 inhibited FAP with an IC50 value of 14 nM, showing high selectivity against dipeptidyl peptidase (DPP)-related enzymes and prolyl oligopeptidase (PREP). BR103354 exhibited good pharmacokinetic properties as evidenced by oral bioavailability of 48.4% and minimal hERG inhibition. Single co-administration of BR103354 with hFGF21 reduced nonfasting blood glucose concentrations, in association with increased intact form of hFGF21 in ob/ob mice. BR103354 acts as an effective FAP inhibitor in vitro and in vivo, thereby demonstrating its potential application as an anti-diabetic and anti-NASH agent.

INU-101 is an 11β-HSD1 inhibitor. In KKAy mice, ob/ob mice, and ZDF rats, oral administration of INU-101 led to enhanced insulin sensitivity and the lowering of the fasting level of glucose in the blood. INU-101 therefore shows promise as a potential treatment for type 2 diabetes and metabolic syndrome.

BMS-763534 is a potent antagonist of corticotropin-releasing factor/hormone receptor 1 (CRHR-1).

4-Aaqb, also known as OB-318, is a natural inhibitor of the autophagy pathway, enhancing immune function, suppressing MAPK and NFκB, showing anti-inflammatory, hypoglycemic, vasorelaxative, and antiproliferative activities.

Gastric inhibitory peptide 1 (GIP-1) (3-42), a fragment of the incretin hormone GIP and antagonist to the GIP receptor, is generated through the action of serum dipeptidyl peptidase 4 (DDP-4). When administered at 25 nmol/kg to an ob/ob mouse diabetes model, GIP-1 (3-42) elevates plasma glucose levels and lowers plasma insulin levels, demonstrating its effect on reducing insulin secretion from BRIN-BD11 pancreatic cells at a concentration of 100 nM.

ZG-2291 is a selective inhibitor targeting FIH (hypoxia-inducible factor inhibitor) with oral activity. It selectively inhibits FIH by binding to it and inducing a conformational flip in a catalytically crucial tyrosine, without affecting other 2OG oxidases of the JmjC subfamily. ZG-2291 promotes thermogenesis and ameliorates obesity symptoms and metabolic dysfunctions in ob/ob mice. This compound holds promise for research in the field of obesity-related diseases.

Leptin(22-56),human is a peptide fragment of Leptin, which ACTS through a variety of subtypes of Ob-Rs.

GIP receptor antagonist (IC50 = 2.6μM). Inhibits GIP-stimulated insulin release from pancreatic β cells in vitro. In ob/ob mice, blocks the effects of GIP on insulin release and plasma glucose levels. Also improves intraperitoneal glucose tolerance, insul

MK-0812 is a dual antagonist of the CCR2 and CCR5 receptors that can alleviate adipose inflammation in ob/ob mice.